Obstructive Sleep Apnea and Sickle Cell Anemia

WHAT’S KNOWN ON THIS SUBJECT: Obstructive sleep apnea syndrome (OSAS) prevalence in children with sickle cell anemia is not well described. Although these children often experience nocturnal oxygen desaturation, it is unclear whether they are more likely to have OSAS.

WHAT THIS STUDY ADDS: Children with sickle cell anemia have a high prevalence of OSAS with typical symptoms, beyond just nocturnal oxyhemoglobin desaturation. This study supports the need for increased efforts to screen for, diagnose, and treat OSAS in this vulnerable population.

.abstract

OBJECTIVE: To ascertain the prevalence of and risk factors for obstructive sleep apnea syndrome (OSAS) in children with sickle cell anemia (SCA).

METHODS: Cross-sectional baseline data were analyzed from the Sleep and Asthma Cohort Study, a multicenter prospective study designed to evaluate the contribution of sleep and breathing abnormalities to SCA-related morbidity in children ages 4 to 18 years, unselected for OSAS symptoms or asthma. Multivariable logistic regression assessed the relationships between OSAS status on the basis of overnight in-laboratory polysomnography and putative risk factors obtained from questionnaires and direct measurements.

RESULTS: Participants included 243 children with a median age of 10 years; 50% were boys, 99% were of African heritage, and 95% were homozygous for HbS hemoglobin. OSAS, defined by obstructive apnea hypopnea indices, was present in 100 (41%) or 25 (10%) children at cutpoints of $10$ or $5$, respectively. In univariate analyses, OSAS was associated with higher levels of habitual snoring, lower waking pulse oxygen saturation ($\text{SpO}_2$), reduced lung function, less caretaker education, and non-preterm birth. Lower sleep-related $\text{SpO}_2$ metrics were also associated with higher obstructive apnea hypopnea indices. In multivariable analyses, habitual snoring and lower waking $\text{SpO}_2$ remained risk factors for OSAS in children with SCA.

CONCLUSIONS: The prevalence of OSAS in children with SCA is higher than in the general pediatric population. Habitual snoring and lower waking $\text{SpO}_2$ values, data easily obtained in routine care, were the strongest OSAS risk factors. Because OSAS is a treatable condition with adverse health outcomes, greater efforts are needed to screen, diagnose, and treat OSAS in this high-risk, vulnerable population.

PEDiatrics 2014;134:273–281
Obstructive sleep apnea syndrome (OSAS) is a disorder of breathing during sleep in which episodic upper airway collapse disrupts ventilation and leads to oxyhemoglobin desaturation and poor sleep quality. This common pediatric disorder, with a prevalence of 1% to 5%, is associated with adverse health outcomes, such as behavioral problems, daytime sleepiness, cognitive deficits, cardiovascular changes, and reduced quality of life. In adults, untreated OSAS is associated with increased risk of incident cardiovascular disease and stroke. Adenotonsillar hypertrophy is the most commonly identified risk factor for childhood OSAS and adenotonsillectomy is effective treatment. Otherwise normal children with OSAS are more likely to be African-American, exposed to environmental tobacco smoke, born preterm, have undergone adenotonsillectomy, and live in disadvantaged neighborhoods. It is unknown whether these risk factors generalize to children with sickle cell anemia (SCA).

SCA affects 1 in 600 African-Americans and is characterized by chronic hemolytic anemia and complications related to recurrent vaso-occlusion. One of the strongest triggers for vaso-occlusion is oxyhemoglobin desaturation, which has been linked to several complications of SCA, such as increased pain, greater risk of central nervous system events, cognitive dysfunction, and history of acute chest syndrome. Oxyhemoglobin desaturation is a well-known phenomenon in SCA resulting from a combination of calibration of the pulse oximeter for hemoglobin A, and not hemoglobin S, a rightward shift of the oxyhemoglobin dissociation curve, and dyshemoglobins, which are elevated in the presence of intravascular hemolysis but incapable of transporting oxygen. Because desaturation is common to both SCA and OSAS, the relationship between SCA and OSAS is of great interest.

The prevalence of OSAS in children with SCA is not well defined, and there is uncertainty whether OSAS is more common in this disorder. Previously reported prevalence rates range from 5% to 79%. Except for 1 study, prevalence estimates have been based on samples clinically referred for OSAS or with desaturation. Furthermore, clinicians are uncertain whether the same symptoms, signs, and risk factors associated with OSAS in otherwise healthy children have clinical utility in screening for OSAS in children with SCA.

We used data from participants in the prospective Sleep and Asthma Cohort Study who were unslected for OSAS symptoms to investigate the prevalence and risk factors for OSAS in children with SCA. We hypothesized that children with SCA will have a higher than expected prevalence of OSAS for children of African heritage and that higher obstructive apnea hypopnea indices (OAHIs) will be associated with more OSAS symptoms and greater nocturnal oxyhemoglobin desaturation.

METHODS

A detailed description of the testing procedures and statistical approach is provided in the Supplemental Information. In brief, we conducted a cross-sectional analysis of baseline data collected as part of the Sleep and Asthma Cohort Study, a prospective observational cohort of children ages 4 to 18 years with SCA (homozygous for sickle cell hemoglobin [HbSS] or compound heterozygotes for sickle β thalassemia zero [HbSβ0]), designed to evaluate the contribution of asthma and sleep abnormalities to SCA-related morbidity. Participants were recruited (66% participation rate) from 3 pediatric centers: St Louis, Missouri; Cleveland, Ohio; and London, United Kingdom. Children were enrolled without regard to past morbidity from or symptoms of sleep-disordered breathing or asthma. Children were ineligible for participation if they themselves were smokers, receiving long-term blood transfusions, or receiving long-term continuous positive airway pressure therapy at the time of enrollment; were participating in a clinical trial evaluating blood transfusion, oxygen, or hydroxyurea therapy; had chronic lung disease (other than asthma); or were HIV positive. Participants placed on transfusion therapy during the study were retained in the cohort. Institutional review boards for each site approved the study protocol. Written informed parental consent and patient assent were obtained for all participants.

Questionnaires and Definitions

Parents/primary caretakers of participants completed standardized questionnaires about demographic characteristics and medical history, including asthma, allergies, and sleep. Asthma was defined as a “yes” response to any of the following 3 questions: (1) “Has a doctor ever said that the participant has asthma?” (2) “Does the participant take any asthma medications?”, and (3) “Does the participant still have asthma?” Hayfever was defined as a “yes” response to “Has a doctor ever said that the participant has hayfever?” Household tobacco smoke exposure was defined as a “yes” response to current exposure.

Habitual snoring was assessed by using the sleep questionnaire by response to “How many times did your child snore in the previous month?” and was defined as snoring ≥3 nights per week. Trouble breathing or witnessed apnea were defined when these symptoms occurred at least “sometimes” (1 to 2 times per week). Enuresis was defined as bedwetting at least 1 to 2 times per week. Previous tonsillectomy or adenoidectomy was indicated by a “yes” response to removal of tonsils or adenoids.
adenoids. Family history of OSAS was defined as positive if there were any “yes” responses to a family member either diagnosed with OSAS or using continuous positive airway pressure. Sleepiness was assessed by using the Epworth Sleepiness Scale modified for children, in which scores range from 0 to 24, with higher scores indicating greater daytime sleepiness.29

Physiologic assessments included standardized measurements of height, weight, BMI converted to age- and gender-adjusted z scores,30 and blood pressure converted to age-, gender-, and height-adjusted systolic and diastolic percentiles based on auscultatory normative data for children with SCA.31 Allergy skin tests using the prick puncture technique with the multitest (Lincoln Diagnostics, Decatur, IL) to 9 Aeroallergens were performed as previously reported.32 Atopy was defined as having at least 2 positive skin tests.

Spirometry measures (forced expiratory volume in 1 second [FEV1], forced vital capacity [FVC], and the ratio of FEV1 to FVC [FEV1:FVC]) were performed by study-certified technicians with the use of standardized protocols33,34 and compared with normative data for healthy black children.34,35 Waking pulse oxygen saturation (SpO2) values were collected by using a standardized 5-minute period. Other laboratory data were collected as part of clinical care. Children underwent full channel, in-laboratory polysomnography by study-certified technicians with standardized protocols and equipment following American Academy of Sleep Medicine guidelines for data acquisition and scoring, except for carbon dioxide, which was not collected.36 Because there is no consensus about what OAHI threshold should be used to define OSAS status, OAHI data were summarized by using several commonly used pediatric cutpoints: OAHI ≥1.5,37 OAHI ≥2,40 and OAHI ≥5.4–6.38

Primary snoring was defined as an OAHI value of <1 with habitual snoring 3 to 5 nights per week.

Statistical Analyses

Means, SDs, medians, and interquartile ranges were computed for continuous variables. Frequencies and percentages were computed for categorical variables. Continuous data were analyzed by using analysis of variance or the non-parametric equivalent for nonnormal distributions. Categorical data were analyzed with a χ2 test, and the Fisher’s exact test was used where expected cell counts did not meet minimum requirements. Logistic regression was used for the multivariable analyses to assess the association between potential risk factors and OSAS status. For analytic purposes, the dependent variable, OAHI, was categorized into 3 OSAS status groups: no OSAS (OAHI <1), mild OSAS (1 ≤ OAHI <5), and moderate to severe OSAS (OAHI ≥5). Associations between the risk factors and OSAS status were expressed as odds ratios (ORs) with 95% confidence intervals (CIs). All tests for significance were 2-tailed. P values of <.05 were considered significant. All analyses were performed by using SPSS version 21 (IBM SPSS Statistics, IBM Corporation, Armonk, NY).

RESULTS

The final analytic sample included 243 children: 59 (24%) from Cleveland, 94 (39%) from London, and 90 (37%) from St Louis. The median age was 10 years, 50% were boys, 99% had African heritage, and 95% were homozygous for HbSS. The OAHI data were not normally distributed: mean (SD, range) = 2.1 (4.6, 0–37.2), whereas the median (interquartile range) was 0.6 (0.2–1.9). Figure 1 shows the prevalence of OSAS based on commonly used OAHI cutoffs and definitions: 41% for an OAHI ≥1, 34% for an OAHI ≥1 plus habitual snoring, 28% for an OAHI ≥1.5, 24% for an OAHI ≥2, and 10% for an OAHI ≥5. Among the 143 (59%) participants with OAHI values <1, 21% were habitual snorers (at least 3–5 nights per week) and 48% snored at least 1 to 2 nights per week.

Participant Characteristics and OSAS Symptoms by OAHI Categories

Table 1 shows associations of participant characteristics and OSAS symptoms by OAHI categories. The frequency of OSAS symptoms (habitual snoring, trouble breathing, witnessed apnea, nocturnal enuresis) increased with higher OAHI values but not for nocturnal restlessness or daytime sleepiness. Only less caretaker education varied significantly with increasing OAHI values, whereas age, male gender, and

FIGURE 1

OSAS status at different OAHI cutoffpoints. ICSD-II, International Classification of Sleep Disorders II.
TABLE 1 Distribution of Participant Characteristics and OSAS Symptoms by OAHI Categories

<table>
<thead>
<tr>
<th>Demographic characteristics</th>
<th>All (N = 245)</th>
<th>OAHI &lt;1 (n = 143, 59%)</th>
<th>OAHI ≥1 and &lt;2 (n = 42, 17%)</th>
<th>OAHI ≥2 and &lt;5 (n = 33, 14%)</th>
<th>OAHI ≥5 (n = 25, 10%)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>10.6 (4.2)</td>
<td>10.6</td>
<td>11.1</td>
<td>11.4</td>
<td>8.8</td>
<td>.11</td>
</tr>
<tr>
<td>Male gender, %</td>
<td>50.2</td>
<td>47.6</td>
<td>50.0</td>
<td>48.5</td>
<td>68.0</td>
<td>.31</td>
</tr>
<tr>
<td>Caretaker education less than high school (n reported = 239), %</td>
<td>39.3</td>
<td>33.1</td>
<td>50.0</td>
<td>57.6</td>
<td>32.0</td>
<td>.03</td>
</tr>
<tr>
<td>Household income &lt;$30,000 (n reported = 207), %</td>
<td>59.9</td>
<td>56.3</td>
<td>73.0</td>
<td>61.3</td>
<td>55.0</td>
<td>.32</td>
</tr>
</tbody>
</table>

Sleep and breathing symptoms

| Habitual snoring ≥3 nights/week (n reported = 232), % | 34.0 | 21.1 | 36.8 | 50.0 | 80.0 | <.001 |
| Trouble breathing ≥1 night/week (n reported = 219), % | 19.2 | 14.0 | 13.2 | 25.9 | 48.0 | .001 |
| Witnessed apnea ≥1 night/week (n reported = 218), % | 9.2 | 5.6 | 2.6 | 14.3 | 32.0 | <.001 |
| Nocturnal enuresis, ≥1 night/week (n reported = 227), % | 30.0 | 27.6 | 20.0 | 32.9 | 56.0 | .016 |
| Restless, ≥1 night/week, % | 31.7 | 32.9 | 33.3 | 30.3 | 24.0 | .84 |
| Epworth Sleepiness Scale* (n reported = 237), mean (SD) | 7.1 (4.2) | 7.0 | 6.9 | 8.1 | 7.0 | .59 |

Physiologic measurements

| Hemoglobin, mean (SD), g/dL | 8.2 (1.2) | 8.4 | 8.1 | 8.0 | 7.9 | .10 |
| Waking SpO2, median (IQR), % | 97.1 (94.0 to 98.6) | 98.3 | 98.5 | 94.0 | 95.8 | <.001 |
| BMI z score (n reported = 241), median (IQR) | 0.02 (-0.71 to 0.82) | 0.08 | 0.04 | -0.10 | -0.02 | .90 |
| Systolic blood pressure >90th percentile (n reported = 241), % | 23.7 | 27.7 | 11.9 | 21.2 | 24.0 | .1 |
| Diastolic blood pressure >90th percentile (n reported = 240), % | 2.5 | 2.1 | 2.4 | 3.0 | 4.0 | .05 |
| Atopy (>2 positive skin tests; n reported = 217), % | 26.3 | 25.0 | 26.3 | 37.9 | 18.2 | .41 |
| FVC (n reported = 241), % predicted | 92.2 (14.3) | 93.8 | 89.6 | 92.0 | 87.8 | .13 |
| FEV1 (n reported = 241), % predicted | 88.0 (15.8) | 90.7 | 84.3 | 85.6 | 84.4 | .003 |
| FEV1/FVC (n reported = 241) | 0.86 (0.07) | 0.87 | 0.85 | 0.81 | 0.87 | <.001 |

Other medical and/or family history, %

| Previous tonsillectomy or adenoidectomy (n reported = 240) | 19.6 | 17.6 | 28.6 | 16.1 | 20.0 | .43 |
| Household smoking exposure (n reported = 241) | 28.6 | 27.0 | 23.8 | 39.4 | 32.0 | .44 |
| Asthma | 27.6 | 23.1 | 35.7 | 33.3 | 32.0 | .3 |
| Hayfever (n reported = 196) | 18.9 | 20.0 | 15.8 | 18.5 | 18.8 | .95 |
| Preterm birth (n reported = 233) | 12.0 | 17.0 | 7.5 | 0.0 | 8.0 | .03 |
| Prescribed hydroxyurea at time of polysomnography (n reported = 218), % | 10.3 | 12.6 | 9.5 | 6.1 | 4.0 | .46 |

Family history of OSAS or CPAP use (n reported = 239) | 10.0 | 9.2 | 17.1 | 12.5 | 0.0 | .15 |

Continuous data with normal distributions are reported as means (SD), whereas data with nonnormal distributions are reported as medians (IQR). Categorical data are reported as a percentage of the entire sample (N = 245) or numbers (n reported, IQR, interquartile range; CPAP, continuous positive airway pressure.

* The range for the Epworth Sleepiness Scale score is 0 to 24, with higher scores indicating greater daytime sleepiness and normal values ≤11 in children.

Household income did not. Lower waking SpO2 values were significantly associated with greater OAHI values, whereas lower hemoglobin values, higher BMI z scores, and elevated blood pressure were not. Participants with SCA were rarely obese. Greater OAHI values were significantly associated with reduced lung function (lower FEV1 and FEV1/FVC), but not with lower FVC. Preterm birth was associated with lower, not higher, apnea hypopnea index (OAHI) values. Other potential OSAS risk factors, such as family history of OSAS, previous adenotonsillectomy, and other allergic or inflammatory conditions (asthma, hayfever, atopy, and environmental tobacco smoke exposure), were not associated with increasing OAHI. Hydroxyurea prescription was caretaker reported for 10% of the sample but was not associated with lower OAHI (P = .46).

**Polysomnography Findings and Oximetry Metrics by Increasing OAHI Cutpoints**

Polysomnography results stratified by OAHI cutpoints are shown in Table 2 for cardiorespiratory data and are shown in Table 3 for sleep data. Higher OAHI cutpoints were significantly associated with higher respiratory and desaturation indices and lower SpO2 metrics. Obstructive apneas had a negligible contribution to the overall OAHI at cutpoints <2. Central apneas tended to be more frequent with higher OAHLs, but remained within the normal range. Higher arousal index was the only sleep variable associated with higher OAHI cutpoints (P < .001).

**Risk Factors for OSAS: Multivariable Models Using 2 OSAS Severity Groups**

Table 4 summarizes the final multivariable models in which the dependent variable, OSAS status, is categorized into 3 groups: no OSAS (OAHI <1), mild OSAS (1 ≤ OAHI <5), and moderate to severe OSAS (OAHI ≥5). When the β-value is negative, significant associations will have ORs <1, which means that a lower variable value is associated with a greater odds of being a member of the
OSAS group. To improve clinical interpretability of the significant, but large, negative ORs, we “reformatted” waking SpO2 values <96% to present the effect with an OR >1 and recoded preterm birth as non–preterm birth.

There were 218 participants in the 2 groups: a no-OSAS group and a mild–OSAS group. In the screening model with 13 variables of interest, 186 of 218 participants had full data (loss of 14.7%) and the following 6 variables passed screening with \( P < .20 \): habitual snoring, waking SpO2 <96%, FEV1 percent predicted, environmental tobacco smoke exposure, caretaker education less than high school, and non–preterm birth. By using the 6 variables from the first step with the 186 participants to estimate a reduced model, multivariable analyses revealed that 4 variables were significantly and independently associated with a greater odds of mild OSAS: waking SpO2 values <96% (OR: 7.89; 95% CI: 3.66–17.02; \( P < .001 \)), habitual snoring (OR: 2.76; 95% CI: 1.24–6.17; \( P = .013 \)), lower FEV1 percent predicted (OR: 0.96; 95% CI: 0.93–0.99; \( P = .010 \)), and non–preterm birth (OR: 4.98; 95% CI: 1.1–20.97; \( P = .028 \)). The final model was 57.6% accurate at predicting mild OSAS in this sample (sensitivity = 0.78, specificity = 0.67; given a prevalence rate of 31% for mild OSAS in this sample, the positive predictive value was 0.52 and the negative predictive value was 0.87).

For no OSAS versus moderate to severe OSAS (OAHI \( \geq 5 \)), there were 168 participants. With the use of the 4 variables from the final model for mild OSAS (plus age and gender) in the model for moderate to severe OSAS (OAHI \( \geq 5 \)), there were 148 participants with full data (loss of 11.9%). Multivariable analyses revealed that only 2 factors significantly and independently associated with moderate to severe OSAS status: habitual

### Table 2: Cardiorespiratory Polysomnography Variables by OAHI Diagnostic Cutpoints

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All (( N = 243 ))</th>
<th>OAHI &lt;1 (( n = 143 ))</th>
<th>OAHI ( \geq 1 ) (( n = 100 ))</th>
<th>OAHI ( \geq 2 ) (( n = 58 ))</th>
<th>OAHI ( \geq 5 ) (( n = 25 ))</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>OAHI</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>In NREM, median (IQR)</td>
<td>0.25 (0.0–0.18)</td>
<td>0.0</td>
<td>0.0</td>
<td>0.85</td>
<td>1.68</td>
<td>4.62 &lt;.001</td>
</tr>
<tr>
<td>In REM, median (IQR)</td>
<td>2.0 (0.0–0.80)</td>
<td>1.00</td>
<td>4.5</td>
<td>11.0</td>
<td>47.0</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Median (IQR)</td>
<td>0.00</td>
<td>0.0</td>
<td>0.0</td>
<td>0.13</td>
<td>0.71</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Central apnea index, median (IQR)</td>
<td>0.29 (0.12–0.68)</td>
<td>0.24</td>
<td>0.50</td>
<td>0.35</td>
<td>0.38</td>
<td>.005</td>
</tr>
<tr>
<td>Sleep-wake SpO2 difference (mean reported = 238), %</td>
<td>0.85 (1.74)</td>
<td>0.63</td>
<td>0.90</td>
<td>1.24</td>
<td>1.46</td>
<td>.073</td>
</tr>
</tbody>
</table>

Continuous data with normal distributions are reported as means (SD), whereas data with nonnormal distributions are reported as medians (IQR). Categorical data are reported as a percentage of the entire sample (\( N = 243 \)) or the numbers (\( n \)) of participants reported. IQR, interquartile range; NREM, nonrapid eye movement; REM, rapid eye movement.

### Table 3: Sleep Polysomnography Variables by OAHI Diagnostic Cutpoints

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>All (( N = 243 ))</th>
<th>OAHI &lt;1 (( n = 143 ))</th>
<th>OAHI ( \geq 1 ) (( n = 100 ))</th>
<th>OAHI ( \geq 2 ) (( n = 58 ))</th>
<th>OAHI ( \geq 5 ) (( n = 25 ))</th>
<th>( P )</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total sleep time, mean (SD), min</td>
<td>438.7 (88.2)</td>
<td>438.4</td>
<td>450.2</td>
<td>431.5</td>
<td>430.9</td>
<td>.60</td>
</tr>
<tr>
<td>Sleep latency, median (IQR), min</td>
<td>20.5</td>
<td>20.0</td>
<td>24.8</td>
<td>20.5</td>
<td>15.0</td>
<td>.88</td>
</tr>
<tr>
<td>REM latency, median (IQR), min</td>
<td>83.5</td>
<td>80.8</td>
<td>89.0</td>
<td>92.0</td>
<td>90.0</td>
<td>.28</td>
</tr>
<tr>
<td>Sleep efficiency, median (IQR), %</td>
<td>85.5 (78.8–89.5)</td>
<td>85.8</td>
<td>84.5</td>
<td>84.4</td>
<td>82.2</td>
<td>.21</td>
</tr>
<tr>
<td>NREM stage 1 sleep, mean (SD), %</td>
<td>5.2 (2.7)</td>
<td>5.0</td>
<td>5.0</td>
<td>5.9</td>
<td>5.8</td>
<td>.22</td>
</tr>
<tr>
<td>NREM stage 2 sleep, mean (SD), %</td>
<td>45.6 (8.2)</td>
<td>45.5</td>
<td>46.7</td>
<td>45.5</td>
<td>44.7</td>
<td>.78</td>
</tr>
<tr>
<td>NREM stage 3 sleep, mean (SD), %</td>
<td>22.5 (8.1)</td>
<td>22.4</td>
<td>20.9</td>
<td>22.7</td>
<td>25.7</td>
<td>.13</td>
</tr>
<tr>
<td>REM sleep, mean (SD), %</td>
<td>26.6 (6.3)</td>
<td>27.0</td>
<td>27.3</td>
<td>25.9</td>
<td>23.9</td>
<td>.10</td>
</tr>
<tr>
<td>Supine sleep time, mean (SD), min</td>
<td>46 (0.26)</td>
<td>.47</td>
<td>.42</td>
<td>41</td>
<td>57</td>
<td>.09</td>
</tr>
<tr>
<td>Arousal index, mean (SD) events/hr</td>
<td>8.6 (3.0)</td>
<td>8.2</td>
<td>8.3</td>
<td>9.1</td>
<td>10.9</td>
<td>&lt;.001</td>
</tr>
</tbody>
</table>

Continuous data with normal distributions are reported as means (SD), whereas data with nonnormal distributions are reported as medians (IQR). IQR, interquartile range; NREM, nonrapid eye movement; REM, rapid eye movement.
TABLE 4 Final Models of Logistic Regression Predicting OSAS at 2 Severity Levels

<table>
<thead>
<tr>
<th>β</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender</td>
<td>0.331</td>
<td>1.39</td>
</tr>
<tr>
<td>Age</td>
<td>0.031</td>
<td>1.01</td>
</tr>
<tr>
<td>Waking SpO2 values &lt;96%*</td>
<td>-2.085</td>
<td>0.13</td>
</tr>
<tr>
<td>Habitual snoring</td>
<td>1.016</td>
<td>2.76</td>
</tr>
<tr>
<td>FEV1, percent predicted*</td>
<td>-0.041</td>
<td>0.96</td>
</tr>
<tr>
<td>Caretaker education &lt; high school</td>
<td>0.546</td>
<td>1.73</td>
</tr>
<tr>
<td>Non–preterm birth</td>
<td>1.606</td>
<td>4.98</td>
</tr>
<tr>
<td>Environmental tobacco smoke exposure</td>
<td>0.550</td>
<td>1.73</td>
</tr>
</tbody>
</table>

No OSAS versus OAHI <5

<table>
<thead>
<tr>
<th>β</th>
<th>OR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male gender</td>
<td>0.836</td>
<td>2.31</td>
</tr>
<tr>
<td>Age</td>
<td>-0.122</td>
<td>0.89</td>
</tr>
<tr>
<td>Waking SpO2 values &lt;96%*</td>
<td>-1.706</td>
<td>0.18</td>
</tr>
<tr>
<td>Habitual snoring</td>
<td>2.829</td>
<td>16.83</td>
</tr>
<tr>
<td>FEV1, % predicted</td>
<td>-0.320</td>
<td>0.97</td>
</tr>
<tr>
<td>Caretaker education less than high school</td>
<td>0.500</td>
<td>1.65</td>
</tr>
<tr>
<td>Non–preterm birth</td>
<td>1.026</td>
<td>2.79</td>
</tr>
<tr>
<td>Environmental tobacco smoke exposure</td>
<td>-0.247</td>
<td>0.79</td>
</tr>
</tbody>
</table>

No OSAS versus OAHI ≥5

* When the β-value is negative, significant associations will have ORs < 1, which means that a lower variable value is associated with a greater odds of being a member of an OSAS group. To improve clinical interpretability of the significant but negative ORs, we “reformatted” some of them to present the effect with an OR > 1.

**DISCUSSION**

This article summarizes clinical characteristics and polysomnography data from the largest sample of children with SCA, unreferred for signs or symptoms of OSAS. The OSAS prevalence rates, ranging from 41% at a cutpoint of an OAHI ≥1 to 10% at a cutpoint of an OAHI ≥5, are higher than those reported in otherwise normal children (1%–5% at a cutpoint ≥5),5,6 in African-American children (8.7% at a cutpoint ≥5),9 and in a Brazilian cohort of children with SCA (10.6% at a cutpoint ≥1).18

Habitual snoring was a strong risk factor for OSAS in children with SCA, although many of the previously reported risk factors for OSAS for otherwise healthy children were not observed, such as age, gender, obesity, hypertension, daytime sleepiness, asthma, hayfever, atopy, environmental tobacco smoke exposure, family history of OSAS, previous adenotonsillectomy, and preterm birth. The association of enuresis with OSAS was previously reported for this cohort.41 Lower caretaker education was a risk factor in univariate analyses, but not in multivariable analysis. Other unique risk factors to SCA were suggested by univariate analyses (lower waking SpO2 values and reduced lung function).

In otherwise healthy children, habitual snoring is sensitive but not very specific for predicting OSAS. Lower waking SpO2 had the strongest association with mild OSAS followed by habitual snoring, but this order was reversed for OAHI values ≥5, suggesting that OAHI values in the milder range may be less specific for OSAS. The models were only slightly more than 50% predictive of polysomnography-defined OSAS at either range, similar to the positive and predictive values of history and physical examination (65% and 46%, respectively) for the diagnosis of OSAS in otherwise healthy children, which led to the recommendation that objective testing such as polysomnography be used in the diagnosis of OSAS.2 This recommendation becomes even more important in children with SCA in whom other disturbances to oxygen delivery such as anemia, oxyhemoglobin desaturation, and other pulmonary dysfunction are often present.

Although we evaluated OSAS prevalence and risk factors on the basis of commonly used OAHI cutpoints for children, the gold standard for OSAS diagnosis is not polysomnography alone, but rather the skillful integration of clinical and polysomnography findings by experienced clinicians.16 The AHI is a popular metric to determine the presence of OSAS, but there is no consensus on how the AHI should be used to indicate disease severity. Previous
studies have shown that the AHI was not useful in predicting either baseline neurobehavioral morbidity or response to OSAS treatment in children in the general population.\textsuperscript{46,47–53} Even “primary snoring,” that is snoring with an AHI <1, has been associated with neurobehavioral morbidity.\textsuperscript{54–56} For these reasons, we cannot identify an AHI threshold at which OSAS needs to be addressed. Because the study was based on cross-sectional data, the impact of OSAS or greater hypoxemia on health outcomes in children with SCA cannot be assessed. Further outcomes studies are required to determine what threshold is associated with SCA-related morbidity.

Although OSAS appears to be 1 contributor to sleep-disordered breathing in SCA, the oximetry metrics reveal that some children also experience more sustained nocturnal desaturation. Greater desaturation time was associated with higher OAHI cutpoints, but desaturation can also be related to comorbid lower respiratory tract pathology. In our sample with SCA, the oximetry metrics for sleep time of \(<95\%\) and \(<92\%\) were similar to the upper limits of normal reported for otherwise healthy children.\textsuperscript{57–59} Nevertheless, the oximetry and lung function findings suggest that a portion of the sleep-disordered breathing in children with SCA may be an indicator of lower respiratory tract problems rather than a specific marker of upper airway obstruction and OSAS.

The strengths of this study include participants who were unselected for symptoms of OSAS, the large multicenter sample, and objective assessment of sleep-disordered breathing by standardized full polysomnography scored centrally without clinical correlates. Nevertheless, several limitations are noted. With a participation rate of 66%, it is possible that the sample included families with greater concerns about sleep-disordered breathing, leading to higher OSAS prevalence rates. We recognize that questionnaire data and parent report of symptoms are imperfect measures of the presence and severity of OSAS\textsuperscript{2} and potential OSAS risk factors. On the other hand, in this cohort, parent report of wheezing symptoms was a better predictor of a physician diagnosis of asthma than lung function testing.\textsuperscript{60} In terms of data collection, tonsil size was not assessed, end-tidal carbon dioxide was not measured, and daytime behavioral problems were not evaluated, so the assessment of OSAS signs, symptoms, and consequences could have been more comprehensive. Finally, although validated in comparison with arterial saturation in patients with SCA,\textsuperscript{61} simple pulse oximetry may underestimate oxygenation status because the dyshemoglobins are not measured.\textsuperscript{62}

CONCLUSIONS
This study confirms that children with SCA have a higher prevalence of sleep-disordered breathing consistent with OSAS, beyond greater nocturnal desaturation, and that these children experience typical nocturnal symptoms of snoring and breathing/sleep disturbances. Because OSAS is a treatable condition with adverse health outcomes, greater efforts are needed to implement and evaluate procedures for screening, diagnosing, and treating OSAS in this high-risk, vulnerable population.

ACKNOWLEDGMENTS
We thank the following individuals at the 3 study sites and the coordinating site (Vanderbilt University, Nashville TN): St Louis site: Washington University: Joshua Field, MD, Lisa Garrett, RN, CCRP, Pamela Bates, CRT, RPFT, RPSGT, Rick Talbert, RPSGT, Sabrina Lockett, RPSGT, Valerie Morgan, RRT, Phillip Blanks, and Tinishia Greene. Cleveland site: Case Western Reserve University: Susan Surovec, BA, Nancy Scott, BS, REEG/EPT, RPSGT, REDT, CNIM, and Mary DeBarr, RN, BSN. London site: University College of London Institute of Child Health and Great Ormond Street Hospital: Jane Kirkby, BSc, Satwinder Sahota, BSc, Liam Welsh, PhD, Ursula Johnson, RN, Aidan Laverty, MSc, MBCC, and Anne O’Reilly, North Middlesex Hospital: Anne Yardumian, MD, FRCP, and Marilyn Roberts-Harewood, MRCPCH; University of York: Avijit Kumar Datta, MD, MRCP, Nashville: Ms Dionna O. Roberts, MPH, MS.

REFERENCES


43. Boyd JH, Macklin EA, Strunk RC, DeBaun MR. Asthma is associated with increased mortality in individuals with sickle cell anemia. Haematologica. 2007;92(8):1115–1118


47. Chervin RD, Archbold KH. Hyperactivity and polysomnographic findings in children
evaluated for sleep-disordered breathing. *Sleep.* 2001;24(3):313–320


(Continued from first page)

Dr Rosen helped develop the data collection instruments for sleep, supervised sleep data collection at 1 site, designed the concepts for this manuscript, interpreted the data, created the final draft, and revised the manuscript for final submission; Dr Debaun was the principal investigator for the National Institutes of Health–sponsored Sleep and Asthma Cohort (SAC) project and the principal investigator for 1 site and reviewed and helped revise the manuscript; Dr Strunk contributed to the development of the SAC project, study concepts, and procedures; supervised the quality assurance for pulmonary function testing; and reviewed and helped revise the manuscript; Dr Redline developed the procedures for sleep data collection and analysis, was the principal investigator for 1 site, oversaw the quality of the acquired sleep study data, and reviewed and helped revise the manuscript; Dr Seicean performed data acquisition and analysis at 1 site and reviewed and helped revise the manuscript; Dr Craven contributed as a coinvestigator at 1 site, supervised patient data collection, monitored patient safety, and reviewed and helped revise the manuscript; Ms Gavlak performed data acquisition and analysis at 1 site, monitored patient safety, and reviewed and helped revise the manuscript; Drs Wilkey, Inusa, and Roberts were principal investigators for 1 site, supervised patient data collection, monitored patient safety, and reviewed and helped revise the manuscript; Mr Goodpaster was responsible for sleep data analysis, management, and quality assurance and reviewed and helped revise the manuscript; Dr Malow supervised the sleep data analysis, management, and quality assurance and reviewed and helped revise the manuscript; Dr Redgheir developed the statistical approach, performed those analyses, and reviewed the integrity of those analyses; Dr Kirkham was the principal investigator for 1 site, helped develop the concepts for this SAC project and this manuscript; analyzed and interpreted the data, contributed to the development of the initial draft, and reviewed/revised the manuscript; and all authors approved the final manuscript as submitted.

www.pediatrics.org/cgi/doi/10.1542/peds.2013-4223
doi:10.1542/peds.2013-4223

Accepted for publication May 12, 2014

Address correspondence to Carol L. Rosen, MD, Division of Pediatric Pulmonology, Department of Pediatrics, 1100 Euclid Ave, Mailstop 5017, Cleveland, OH 44106.
E-mail: carol.rosen@case.edu

PEDIATRICS (ISSN Numbers: Print, 0031-4005; Online, 1098-4275).

Copyright © 2014 by the American Academy of Pediatrics

FINANCIAL DISCLOSURE: The authors have indicated they have no financial relationships relevant to this article to disclose.

FUNDING: All phases of this study were supported in part by the National Heart, Lung, and Blood Institute (NIH 1R01HL079857 [Dr Debaun]), UL1 RR024989 Case Western Reserve University Clinical Research Unit and by Research and Development in the National Health Service (United Kingdom). Funded by the National Institutes of Health (NIH).

POTENTIAL CONFLICT OF INTEREST: The authors have indicated they have no potential conflicts of interest to disclose.
Obstructive Sleep Apnea and Sickle Cell Anemia


*Pediatrics* 2014;134;273

DOI: 10.1542/peds.2013-4223 originally published online July 14, 2014;

Updated Information & Services

including high resolution figures, can be found at:

http://pediatrics.aappublications.org/content/134/2/273

Supplementary Material

Supplementary material can be found at:

http://pediatrics.aappublications.org/content/suppl/2014/07/09/peds.2013-4223.DCSupplemental

References

This article cites 57 articles, 13 of which you can access for free at:

http://pediatrics.aappublications.org/content/134/2/273.full#ref-list-1

Subspecialty Collections

This article, along with others on similar topics, appears in the following collection(s):

Hematology/Oncology

http://classic.pediatrics.aappublications.org/cgi/collection/hematology/oncology_sub

Blood Disorders

http://classic.pediatrics.aappublications.org/cgi/collection/blood_disorders_sub

Sleep Medicine

http://classic.pediatrics.aappublications.org/cgi/collection/sleep_medicine_sub

Permissions & Licensing

Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:

https://shop.aap.org/licensing-permissions/

Reprints

Information about ordering reprints can be found online:

http://classic.pediatrics.aappublications.org/content/reprints

Pediatrics is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since . Pediatrics is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2014 by the American Academy of Pediatrics. All rights reserved. Print ISSN: .

American Academy of Pediatrics

DEDICATED TO THE HEALTH OF ALL CHILDREN™
Obstructive Sleep Apnea and Sickle Cell Anemia

Pediatrics 2014;134;273
DOI: 10.1542/peds.2013-4223 originally published online July 14, 2014;

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://pediatrics.aappublications.org/content/134/2/273